ZCI
CTKB icon

Zevenbergen Capital Investments’s Cytek Biosciences CTKB Stock Holding History

Zevenbergen Capital Investments’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42,300
Closed -$386K – 106
2023
Q4 		$386K Buy
42,300
+2,000
+5% +$12.6K 0.01% 92
2023
Q3 		$222K Hold
40,300
– – 0.01% 99
2023
Q2 		$344K Hold
40,300
– – 0.01% 97
2023
Q1 		$370K Buy
+40,300
New +$433K 0.01% 96

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Zevenbergen Capital Investments's CTKB Position: Q1 2024 in Review

Zevenbergen Capital Investments sold out of Cytek Biosciences (CTKB) in Q1 2024, closing a stake of 42,300 shares — an estimated $386K sold.

Zevenbergen Capital Investments first reported a position in CTKB in Q1 2023 and held it in 4 quarters. The position peaked at $386K in Q4 2023. 125 funds tracked by Wall St. Rank hold CTKB as of Q1 2024.

  • Zevenbergen Capital Investments reported no remaining Cytek Biosciences position as of Q1 2024 after selling out during the quarter.
  • Zevenbergen Capital Investments sold 42,300 Cytek Biosciences shares in Q1 2024, an estimated $386K.
  • Zevenbergen Capital Investments first reported a position in Cytek Biosciences in Q1 2023 and held it in 4 quarters.
  • Zevenbergen Capital Investments's Cytek Biosciences position peaked at $386K in Q4 2023.
  • 125 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2024.

Based on Zevenbergen Capital Investments's 13F filing for Q1 2024, filed 7 May 2024.